The Skin Lesions as a Complications of Parkinson’s Disease


Authors: J. Búřil 1;  P. Búřilová 2
Authors‘ workplace: I. neurologická klinika LF MU a FN u sv. Anny v Brně 1;  Ústav zdravotnických informací a statistiky ČR, Praha 2
Published in: Cesk Slov Neurol N 2017; 80(Supplementum 1): 50-53
Category: Original Paper
doi: 10.14735/amcsnn2017S50

Overview

Aim:
We aimed to describe the incidence of pressure lesions (L89) and granulomatous lesion of the skin and subcutaneous tissues (L92) in the selected group of patients with Parkinson‘s disease (PD) (G20).

Material and methods:
We performed a retrospective analysis of data of Parkinson‘s disease patients from hospital information system from the year 2016. Parkinson‘s disease patients were followed in an outpatient Movement Disorder Centre of St. Anne’s University University Hospital in Brno.

Results:
We found 24 patients (3.1%) with pressure lesions and 16 patients (2.1%) with hypergranulations in postoperative scar in place of PEG insertion out of 776 patients (with 3,158 examinations during a selected period) data points. All patients included in the study had a main diagnosis of PD ranging from early form of the disease to a late stage with motor fluctuations and symptoms present (70%). In 94% of patients who suffered from pressure lesions we found partial or complete immobility.

Conclusion:
The incidence of pressure lesions was quite low, which can be cause either by low incidence or by methodological issues on a local level, or by a loss of data from institutional follow up care or home care. We have also found certain level of complications in patients treated by intradudodenal application of L DOPA, i.e. granulations in the skin opening at the point of PEG tube insertion.

Key words:
Parkinson‘s disease – skin lesions – pressure lesions – granulomatosis lesions – complications

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE “uniform requirements” for biomedical papers.


Sources

1. Pfeif­fer RF, Wszolek ZK, Ebadi M. Parkinson‘s Disease. 2nd ed. CRC Press 2012:14– 6.

2. Tarakad A, Jankovic J. Dia­gnosis and Management of Parkinson‘s Disease. Semin Neurol 2017;37(2):118– 26. doi: 10.1055/ s-0037-1601888.

3. National Institue of Neurological Disorders and Stroke. Parkinson‘s Disease Information Page 2017. [online]. Available from URL: https:/ / www.ninds.nih.gov/ Disorders/ Al­l-Disorders/ Parkinsons-Disease-Information-Page.

4. Menšíková K, Bareš M, Kaňovský P, et al. Atypické parkinsonské syndromy. Praha: Galén 2015:13– 21.

5. Majkusová K, Jarošová D. Fal­ls risk factors in an acute –  care setting: a retrospective study. Cent Eur J Nurs Midwifery 2014;5(2):47– 53.

6. Jurásková D. Pády a zranění pa­cientů v souvislosti s poskytováním zdravotní a sociální péče. Ošetřovatelství teorie a praxe moderního ošetřovatelství 2008;10(34):58– 75.

7. Bareš M, Kianička B. Léčba Parkinsonovy nemoci. Neurol Praxi 2014;15(2):105– 8.

8. Leibson CL, Maraganore DM, Bower JH, et al. Comorbid conditions as­sociated with Parkinson’s dis­ease: a population-based study. Mov Disord 2006;21(4):446– 55.

9. Goetz CG, Til­ley BC, Shaftman SR, et al. Movement Disorder Society-sponsored revision of the unified Parkinson’s Disease Rat­ing Scale (MDS-UPDRS): scale presentation and clinimetric test­ing results. Mov Disord 2008;23(15):2129– 70. doi: 10.1002/ mds.22340.

10. Goetz CG, Poewe W, Racol O, et al. Movement Disorder Society Task Force report on the Hoehn and Yahr stag­ing scale: status and recom­mendations. Mov Disord 2004;9(9):1020– 8. doi: 10.1002/ mds.20213.

11. Sorbi S, Hort J, Erkinjuntti T, et al. EFNS-ENS Guidelines on the dia­gnosis and management of disorders as­sociated with dementia. Eur J Neurol 2012;19(9):1159– 79. doi: 10.1111/ j.1468-1331.2012.03784.x.

12. National Parkinson Foundation. Parkinson’s Dis­easeOverview 2016. [online]. Available from URL: www.parkin­son.org/ parkinson-s-disease.aspx.

13. Henchclif­fe C, Severt WL. Disease modification in Parkinson’s disease. Drugs Ag­ing 2011;28(8):605– 15. doi: 10.2165/ 11591320-000000000-00000.

14. Kolektiv autorů. Parkinsonova nemoc z různých pohledů. Společnost Parkinson, Praha 2013. [online]. Dostupné z URL: http:/ / parkinson-help.cz/ tiskova-zprava-2/ .

15. Pokorná A, Benešová K, Mužík J, et al. Sledování dekubitálních lézí u pa­cientů s neurologickým onemocněním –  analýza Národního registru hospitalizovaných. Cesk Slov Neurol N 2016;79(Suppl 1):S8– 14. doi: 10.14735/ amcsn­n2016S8.

16. Fischer M, Gemende I, Marsch W, et al. Skin function and skin disorders in Parkinson’s Disease. J Neur Trans 2001;108(2):205– 13.

17. Beitz JM. Skin and wound is­sues in patients with Parkinson’s disease: an overview of com­mon disorders. Ostomy Wound Manage 2013;59(6):26– 36.

18. Průzkum agentury STEM/ MARK pro Parkinson –  Help, o.s., březen 2015. [online]. Dostupné z URL: http:/ / parkinson-help.cz/ tiskova-zprava-2/ .

19. Pokorná A, Benešová K, Jarkovský J, et al. Pres­sureInjuries in Inpatient Care Facilities in the Czech Republic: Analysis of a National Electronic Database. J WoundOstomy Continence Nurs 2017;44(4):1– 5. doi: 10.1097/ WON.0000000000000344.

Labels
Paediatric neurology Neurosurgery Neurology

Article was published in

Czech and Slovak Neurology and Neurosurgery

Issue Supplementum 1

2017 Issue Supplementum 1

Most read in this issue

This topic is also in:


Login
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account